Ryan Sullivan
Long/short equity, biotech, growth, long-term horizon

Argos Therapeutics: No Light At The End Of The Tunnel

Argos Therapeutics (NASDAQ:ARGS) recently completed its IPO, raising $45 million in an offering at $8/share. This is far below the estimated range of $13-15 for which the company had initially hoped. The stock opened for trading on 02/07/14 at $8.90, and quickly dropped to the offering price of $8/share, with 19,048,958 shares outstanding, for a total market capitalization of $152m.

This company initially filed for an IPO in early 2012, then subsequently withdrew its application, citing market conditions. It would appear that the market was not any kinder to them this time around. Here, I detail my investment thesis on ARGS. As positive as I am on the technology, I would recommend avoiding this stock, as the cash...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
FREESA PRO MEMBERS
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details